Наш асноўны ўклад заключаецца ў тым, што тэрапія ўстойлівага вызвалення аб'ядноўвае перавагі хіміятэрапіі і імунатэрапіі, і ўпершыню яны былі аб'яднаны і прымяняюцца да внутрипухнай тэрапіі праз умяшанне. It integrates local and global treatment, and increases the concentration and time of drug action through sustained release of drugs within the tumor, which not only plays a local anticancer effect of chemotherapy drugs, but also takes into account the role of systemic immunotherapy, thus making up for the shortcomings of other therapies, providing new ideas and approaches for cancer treatment, especially for middle and advanced tumors, especially for reducing tumor recurrence and inhibiting tumor The transfer has Вельмі важнае значэнне; Перавага UMPIC мае перавагу ў выкарыстанні пухліны ў якасці крыніцы антыгена і аўталагічнай вакцыны, што таксама адпавядае тэндэнцыі развіцця персаналізаванай медыцыны. And applied to the clinic, hapten combined with chemotherapy drugs for sustained release treatment of pancreatic cancer primary focus, while inducing distal effect, the essence of which is to induce immune response, T-cell-related CD4, CD8, DC, T and NK cells, and B-cell-related tumor autoantibodies: Antibodies to P53, P16, Cmyc, Zeta, IMP1, Koc, Survivin, p62, HCC1 and other oncogenes, this is the first time to find that T and B are involved in the immune response, and the clinical functions of the distal effect and this therapy was selected for "Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition) jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Альянс інавацыйных умяшанняў умяшання быў апублікаваны ў часопісе клінічнай радыялогіі, том 43, № 19, 2024, 1636-1648.